Pharma Mar SA - Company Profile

Powered by

All the data and insights you need on Pharma Mar SA in one report.

$195 $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date Pharma Mar SA Strategy Report

  • Understand Pharma Mar SA position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Pharma Mar SA: Overview

Select Item

Related keylists

Pharma Mar SA (Pharma Mar) discovers, develops and markets marine-derived drugs to treat cancer. The company’s marketed products include Yondelis (trabectedin) an antitumor agent indicated for the treatment of soft tissue sarcoma and relapsed ovarian cancer in combination with doxorubicin HCl liposome injection; Aplidin (plitidepsin), an anticancer agent for the treatment of multiple myeloma; and Zepzelca (lurbinectedin) for small cell lung cancer. Pharma Mar offers in vitro diagnostic products used for detection of virus and bacteria in respiratory infections and human papilloma virus genotypes, among others. It also offers kits used for diagnosis of influenza A and B and respiratory syncytial virus. Its development pipeline includes PM14 for solid tumors, among others. It also develops RNAi candidates for the treatment of retina diseases. The company has subsidiaries in Germany, Italy, France, Switzerland, the UK, and the US, among others. Pharma Mar is headquartered in Madrid, Spain.

 Gain a 360-degree view of Pharma Mar SA and make more informed decisions for your business Gain a 360-degree view of Pharma Mar SA and make more informed decisions for your business Find out more
Headquarters Spain
Address Avda. De Los Reyes, 1, Pol. Ind. La Mina, Colmenar Viejo, Madrid, 28770
Website www.pharmamar.com/es
Telephone 34 918 466000
No of Employees 509
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange PHM (MCE)
Revenue (2022) $171.0M -19.5% (2022 vs 2021)
EPS XYZ
Net Income (2022) XYZ -97.7% (2022 vs 2021)
Market Cap* $541.5M
Net Profit Margin (2022) XYZ -97.1% (2022 vs 2021)
* As of and is in US$
View Pharma Mar SA financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Pharma Mar SA premium industry data and analytics

180+

Clinical Trials

Determine Pharma Mar SA go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

90+

Catalyst Calendar

Proactively evaluate Pharma Mar SA’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

70+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Pharma Mar SA’s relevant decision makers and contact details.

30+

Pipeline Drugs

Identify which of Pharma Mar SA’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

10+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

7

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

3

Sales & Consensus Forecasts

Understand the current and future drug revenue for Pharma Mar SA and assess market opportunity for new entrants with patient population 8-year forecasts.

3

Marketed Drugs

Understand Pharma Mar SA’s commercialized product portfolio to stay one step ahead of the market.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Pharma Mar SA’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Brands
Yondelis (Trabectedin) – Soft Tissue Sarcoma and Ovarian Cancer :-
Zepzelca (Lurbinectedin) - Small Cell Lung Cancer and Solid Tumors Yondelis
Aplidin - Multiple Myeloma Aplidin
XYZ XYZ
XYZ XYZ
XYZ XYZ
Understand Pharma Mar SA portfolio and identify potential areas for collaboration Understand Pharma Mar SA portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2023 Regulatory Approval In March, the company's Zepzelca (lurbinectedin) has received approval from Swiss Agency for Therapeutic Products (Swissmedic) for the treatment of the metastatic Small Cell Lung Cancer (SCLC).
2023 Regulatory Approval In January, the company's licensing partner, Megapharm Ltd. received the conditional marketing approval for Zepzelca (lurbinectedin) by the Ministry of Health of Israel.
2022 Contracts/Agreements In October, the company entered into an agreement with Klaria Pharma Holding AB to develop an Alginate Film formulation of a PharmaMar compound.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters Pharma Mar SA CTI BioPharma Corp Ability Pharmaceuticals SL Ariad Pharmaceuticals (Spain) SL GP Pharm SA
Headquarters Spain United States of America Spain Spain Spain
City Colmenar Viejo Seattle Barcelona Alcobendas Barcelona
State/Province Madrid Washington Barcelona Madrid Barcelona
No. of Employees 509 128 - - -
Entity Type Public Private Private Private Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Jose Maria Fernandez Sousa-Faro, Ph.D. President; Chief Executive Officer; Chairman Executive Board - -
Maria Luisa de Francia Caballero Chief Financial Officer Senior Management - -
Pedro Fernandez Puentes Vice Chairman Executive Board - -
Luis Mora Capitan Managing Director - Oncology & Virology Business Units Senior Management 2008 -
Heiner Pieper Vice President - Business Development & Licensing Senior Management 2013 -
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Pharma Mar SA key executives to enhance your sales strategy Gain insight into Pharma Mar SA key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward